KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.

Ross Firestone, Alexander M Lesokhin, Saad Z Usmani

Blood Cancer Discov 4(6) 433-436

PMID37824758
PMCIDPMC10618718
DOI10.1158/2643-3230.BCD-23-0176
发表日期2023-10-12
摘要

摘要

In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma. In this article, we review the available data for these three agents, teclistamab, elranatamab, and talquetamab, and discuss practical considerations for their use in clinical settings while the medical community awaits randomized phase III clinical trial datasets comparing them to standard-of-care regimens.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。